Table 1.
Demographic and Clinical Characteristics of Enrolled Patients according to Treatment Group
| DHA Group | Placebo Group | SCA38 Overall | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Group, n = 10a |
| Gender | M | M | F | F | F | F | M | M | F | F | 40% M |
| Age at onset, yr | 38 | 46 | 35 | 38 | 36 | 50 | 44 | 34 | 37 | 26 | 38.4 ± 6.8 |
| Age at evaluation, yr | 46 | 49 | 51 | 49 | 39 | 73 | 47 | 40 | 58 | 35 | 48.7 ± 10.8 |
| SARA score, T0 | 13.5 | 9.0 | 13.0 | 10.0 | 8.5 | 17.5 | 5.0 | 6.0 | 17.5 | 2.5 | 10.2 ± 5.1 |
| ICARS score, T0 | 32.0 | 18.0 | 28.0 | 17.0 | 15.0 | 36.0 | 6.0 | 13.0 | 44.0 | 4.0 | 21.3 ± 13.2 |
| First symptom | Gait ataxia | Gait ataxia | Gait ataxia | Gait ataxia | Gait ataxia | Gait ataxia | Gait ataxia | Gait ataxia | Gait ataxia | Gait ataxia | — |
a
Mean ± standard deviations, otherwise specified.
DHA = docosahexaenoic acid; F = female; ICARS = International Cooperative Ataxia Rating Scale; M = male; SARA = Scale for the Assessment and Rating of Ataxia; SCA38 = spinocerebellar ataxia 38; T0 = time at enrollment.